VTRSViatris
Is it safe?
Elevated bankruptcy risk: a balance sheet under strain. Everything else is secondary until this clears.
Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -83% · now 3% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can VTRS take a bad year?
Viatris carries $12.5B of net debt at 4.95× EBITDA: a heavy load to carry through a bad year.
Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 4.95×
Net debt / EBITDA
- Altman Z-score
- 0.71
Altman Z-score · distress zone, below 1.8
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
Details›
- Total debtQ2 2026
- $13.4B
- Cash and short-term investments
- $887M
- Net debt
- $12.5B
- EBITDA, trailing twelve months
- $2.52B
- Operating profit, trailing twelve months
- −$87M
- Debt / equity
- 0.94×
- Total debt / EBITDA
- 5.30×
- Annualised volatilitytwo years of daily moves
- 34%
- Worst drawdown on file
- −83%
- Below its 52-week high
- 3.3%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry